NGM Biopharmaceuticals Company Updates | Glassdoor

Company Updates

  • We presented data this morning at #ILC2018 from our second Phase 2 study of NGM282 in #NASH; demonstrated clinically significant improvements in #liver histology after just 12 weeks http://glassdoor.com/slink.htm?key=vQz32

    041418 | Press Releases | NGM Bio

    SOUTH SAN FRANCISCO, APRIL 14, 2018 - NGM Bio, a leading biotech company developing a portfolio of clinical-stage product candidates that modulate novel or previously intractable targets implicated in metabolic and other serious diseases, today announced data from a Phase 2 study of its lead product candidate, NGM282, demonstrating clinically meaningful improvements in histological measures of disease in nonalcoholic steatohepatitis (NASH) patients at twelve weeks.

  • NGM President Jeff Jonker describes how we’re building an old school biotech with EBDgroup http://glassdoor.com/slink.htm?key=vQ7HC

  • NGM President Jeff Jonker reflects on career lessons in Biotech, as featured in the SF Business Times http://glassdoor.com/slink.htm?key=vQDN2

    Media Coverage | NGM Bio

    Media Coverage of NGM Bio is a research-driven, clinical stage biopharmaceutical company with a drug discovery engine designed to generate a steady pipeline of first-in-class biologic drug candidates.

Work at NGM Biopharmaceuticals? Share Your Experiences

NGM Biopharmaceuticals
  • Star
  • Star
  • Star
  • Star
  • Star
 
Click to Rate
or